Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution

BACKGROUND: Only 15–20% of pancreatic ductal adenocarcinoma (PDAC) patients are upfront surgical candidates at presentation, and for this cohort of patients, the 5-year survival is a mere 20% despite adjuvant therapy. Previous data indicate that in clinical practice most of these cases are “borderli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Pancreat Cancer
Autors principals: Recio-Boiles, Alejandro, Vondrak, Jessica, Veeravelli, Summana, Mancuso, James J., Saboda, Kathylynn, Roe, Denise J., Riaz, Irbaz Bin, Scott, Aaron J., Elquza, Emad, McBride, Ali, Babiker, Hani M.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170377/
https://ncbi.nlm.nih.gov/pubmed/32313882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc.2020.02.01
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars